Latest Neuren Pharmaceuticals (ASX:NEU) News

Small-cap resources stocks led the week, while takeover activity and strong company results added to the gains. Wellnex Life more than doubled, but sharp falls in Trek Metals and Ionic Rare Earths showed that positive news did not always bring buyers.

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

A tiny gold explorer, a battery materials stock and a biotech name led a week packed with dealmaking, drilling news and fresh funding. Resources did most of the heavy lifting, while several big gaps either held firm or gave back part of their early jump.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Neuren’s partner Acadia secures positive CHMP opinion for DAYBU® in Rett syndrome, paving the way for first EU treatment approval and triggering significant milestone payments for Neuren.

Speculative small caps drove the week, with Tasman Resources, Solis Minerals and Lithium Energy leading the board after funding, drilling and asset sale updates. At the other end, ASX Ltd and Arafura Rare Earths fell hard as investors reacted to higher costs and fresh equity issuance.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.